Key statistics
As of last trade ACADIA Pharmaceuticals Inc (DR6:MUN) traded at 19.68, -16.50% below its 52-week high of 23.57, set on Dec 29, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 19.68 |
|---|---|
| High | 19.68 |
| Low | 19.68 |
| Bid | 19.34 |
| Offer | 19.72 |
| Previous close | 20.04 |
| Average volume | 88.89 |
|---|---|
| Shares outstanding | 169.18m |
| Free float | 168.26m |
| P/E (TTM) | 14.96 |
| Market cap | 3.93bn USD |
| EPS (TTM) | 1.55 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
Press releases
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
- Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
- Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
- Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
More ▼
